



**HIKAL®**

**Hikal Net Sales at Rs. 660.4 crore and EBIDTA increases by 6.4% to Rs. 183.1 crore  
Hikal declares dividend of 25%**

**Mumbai, 16th May 2013:-** Hikal Ltd., the preferred long-term outsourcing partner for leading global life sciences companies, today announced its financial results for the quarter and year ended 31<sup>st</sup> March 2013.

**Performance highlights for the quarter ended 31<sup>st</sup> March 2013**

**Net sales** at Rs. 189.6 crore, up by 24 % as compared to Rs. 152.9 crore in the past quarter  
**PAT** was at Rs. 9.25 crore versus Rs. 9.0 crore up by 2.5% as compared to the past quarter  
**EBIDTA** was up by 13.5% to Rs. 50.1 crore as compared to Rs. 44.1 crore in the past quarter  
**Crop Protection Sales** at Rs.82.6 crore, up by 29.4 % as compared to Rs. 63.9 crore in the past quarter  
**Pharmaceutical Sales** up by 20.1% to Rs. 107.0 crore as compared to Rs. 89.1 crore in the past quarter  
**Dividend** - The Board has declared a final dividend of 25%

**Performance Highlights for the year ended 31<sup>st</sup> March 2012**

**Net sales** at Rs. 660.4 crore versus Rs. 694.2 crore in the previous year, a decrease of 4.9 %  
**PAT** down by 52.9% to Rs. 25.5 crore as compared to Rs. 54.1 crore in the previous year (*due to foreign exchange losses*)  
**EBIDTA** for the year was up by 6.4% at Rs. 183.1 crore as compared to Rs. 172.1 crore in the previous year  
**Crop protection sales** increased by 17.1% to Rs. 288.8 crore, an increase of 17.1% as compared to Rs. 246.50 crore in the previous year  
**Pharmaceutical Sales** down by 17.0 % to Rs. 371.61 crore as compared to Rs. 447.70 crore in the previous year  
**Dividend** - The Board has declared a final dividend of 25%

....2/-

**HIKAL LTD**



:2:

Commenting on the results, **Jai Hiremath, Chairman & Managing Director, Hikal Ltd.** said “Our fourth quarter results have improved significantly as compared to the earlier quarters. Though the sales were lower by 5% for the year, EBTDA grew by 6%. Profit before exchange loss remains virtually the same. But unfortunately due to the foreign exchange loss on forward contracts the net profit was substantially lower.

The Crop Protection division’s business grew by 17% this year. However the Pharmaceutical division was down by 17% mainly on account of lower volumes and price reductions. The volumes have picked up, and with the introduction of new products, business outlook for 2013 ’14 looks positive. Since the foreign exchange contracts are over we expect significantly improved profits in the coming year. ”

**Final dividend**

The Board of Directors has recommended a final dividend of 25% on equity shares for the year ended March 2013 subject to Shareholder’s approval. The Board of Directors has also approved the audited accounts for the financial year ended 31st March 2012.

**About Hikal Ltd.**

Hikal is a reliable long-term outsourcing partner to companies in the Pharmaceuticals, Crop protection Products, and the Specialty and Fine Chemicals industry. The company has been supplying key active ingredients (AI), API’s, intermediates and contract research services, using stringent global quality standards, for its customers in the United States, Europe and Japan. Hikal’s advanced manufacturing facilities have been inspected and approved by leading global players in Crop protection and Pharmaceutical sectors. The crop protection facilities are located at Taloja and Mahad (Maharashtra). Hikal’s manufacturing activities are supported by state-of-the-art research centres in Bangalore and Pune and pilot plant facilities located at Bangalore and Taloja respectively. The API and pharmaceutical intermediates manufacturing facilities are situated in Jigani (Bangalore) and Panoli (Gujarat), respectively.

**For further information contact:**

Hikal Ltd. - **Tejaswini Khadabadi** @ +91 22 3097 3100, Email – [tejaswini\\_khadabadi@hikal.com](mailto:tejaswini_khadabadi@hikal.com)  
 Strategic Growth Advisors Pvt. Ltd.- **Payal Dave** @ +91 22 6114 6679 – [dpayal@sgapl.net](mailto:dpayal@sgapl.net)

**Safe harbor Statement:**

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.

A handwritten signature in blue ink is written over a circular purple stamp. The stamp contains the text "HIKAL LTD." around the top edge and "MUMBAI" in the center, with a star symbol at the bottom.